Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve quality of life and survival rates in patients suffering from pseudomyxoma peritonei. The procedure is long and associated with significant intraoperative blood loss. As such, the anaesthetic management of patients undergoing this procedure can be challenging. The aim of this paper is to describe our perioperative management of pseudomyxoma peritonei patients who received CRS and to report a retrospective audit of our outcomes and complications over a six-year period at a large tertiary centre. A total of 70 patients were included, of whom three (4.3%) had CRS alone, 42 (60.0%) had CRS with HIPEC, and 25 (35.7%) had CRS with HIPEC and early postoperative intraperitoneal chemotherapy. There were no intraoperative deaths. A total of four patients (5.7%) died during their hospital admission. At one-year follow-up, six patients (9.0%) had died, and at the end of the study 15 (22.4%) had died. No statistically significant difference in blood loss was seen between patients who received tranexamic acid (30 patients, 42.9%) and those who did not, but the incidence of deep venous thrombosis was much higher (10/30 versus 1/40). Different intravenous fluid strategies appeared not to influence the incidence of postoperative acute renal failure. Further research is required to evaluate the effects of intraoperative tranexamic acid and different intraoperative fluid strategies on outcomes in patients undergoing CRS with HIPEC.
Pseudomyxoma peritonei (PMP) is an extremely rare epithelial neoplasm that has an incidence of around one to two per million population per year 1, 2 , and is marginally more common in females than males 3 . PMP most commonly originates from the appendix, but can start from other parts of the bowel, ovary or bladder, and is characterised by the progressive intraperitoneal accumulation of mucinous tumour deposition 4 . As this mucinous tumour accumulates, it can cause a wide range of sequelae including ascites, abdominal pain and distension, bowel obstruction, and death 5 . PMP progresses slowly, and rarely metastasises beyond the peritoneum 6, 7 . Despite the slower speed of disease growth, the long-term survival rates are poor, with ten-year survival reported as 10% to 30% 8 . The current gold standard treatment for PMP is a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), which has been shown to improve quality of life and survival rates 2, 5, 9, 10 .
CRS with HIPEC involves the surgical removal of the peritoneum and any intra-abdominal organs affected by PMP, which in our study included the omentum, partial large bowel, appendix and gallbladder. Heated chemotherapy agent is then perfused directly within the abdominal cavity for 60 to 120 minutes. The surgery is extensive, and can last from four hours to over 12 hours 11 . The postoperative period often involves a prolonged hospital stay and numerous complications have been reported including bleeding, sepsis, anastomotic leaks and renal failure 9 . As a result, the perioperative anaesthetic management of patients undergoing CRS with HIPEC can be very challenging.
CRS with HIPEC is known to be associated with significant intraoperative blood loss 12 . Tranexamic acid is a synthetic competitive inhibitor of plasminogen activation and a noncompetitive inhibitor of plasmin that has been shown to reduce bleeding in patients undergoing elective surgery 13 . However, its use in CRS with HIPEC for PMP is not well established 14 .
At present, there is a dearth of literature focusing on the perioperative anaesthetic management of patients undergoing CRS with HIPEC. The majority of previous studies have focused on the intraoperative management [15] [16] [17] , and none of the studies have been based in Australia or New Zealand. The aim of this paper was to describe our perioperative management of these patients and to report an audit of our postoperative complications.
Materials and methods
After obtaining ethical committee approval (approval number: HREC/13/QPAH/63), we retrospectively reviewed information on all patients who underwent CRS with HIPEC for the treatment of PMP in the Department of Surgery, Princess Alexandra Hospital, Brisbane, Australia, over a sixyear period between July 2009 and July 2015. There were no specific exclusion criteria; however, one patient was excluded as their paper chart (hardcopy medical record) was missing. This gave a total of 70 patients who were included in the audit. All patient data was fully de-identified.
Data collection
Paper charts were used to collect anaesthetic and perioperative data, which included patient demographics, intraoperative medication and fluid administration, blood loss, urine output, postoperative pain management and complications. Intraoperative anaesthetic data were collected from an Automated Anaesthesia Record Keeper (WinChart®, Medtel Australia, Sydney, New South Wales). Pathology results were collected from AUSLAB records (Citadel Health, Melbourne, Victoria). Results for renal function, electrolyte balance, liver function, full blood count and clotting profile were recorded preoperatively and at days one, three and five postoperatively. Haemoglobin concentrations at day one and day three postoperatively were used to assess the ongoing postoperative blood loss.
CRS with HIPEC
Patients either underwent extensive CRS alone, CRS with HIPEC, or CRS with HIPEC followed by early postoperative intraperitoneal chemotherapy (EPIC). The specific treatment each patient received was decided by the surgical and oncology teams.
For CRS, peritonectomy was performed with the patient in a modified lithotomy position, as described by Sugarbaker 18 . All organs with visible peritoneal disease were resected. Tissue samples from the resected organs were sent for histopathological examination.
All patients undergoing HIPEC received mitomycin C for 90 minutes with a target temperature range of 39 to 43°C. An open intraoperative approach for HIPEC administration was used, as this allowed even spread of mitomycin throughout the abdominal cavity.
Patients undergoing EPIC received a course of chemotherapy postoperatively. The Sugarbaker completeness of cytoreduction score 18 , summarised in Table 1 , was used to assess prognosis.
Anaesthesia and postoperative care
Due to the complex requirements of these cases, intravenous and intra-arterial access was established in all patients via large bore peripheral intravenous cannulae, arterial lines and central venous lines. Anaesthesia was maintained with propofol or volatile anaesthetic agents. In addition to standard anaesthetic monitoring utilised in our department (electrocardiography, continuous capillary oxygen saturation, inspiratory and expiratory gas analysis), central venous and invasive intra-arterial blood pressure monitoring was established in all patients. Depth of anaesthesia was monitored using bispectral index using the Infinity® BISx® SmartPod® (Drägerwerk, Lübeck, Germany). Stroke volume variation was monitored using the EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA) in order to guide fluid therapy. Intraoperative monitoring of haemoglobin concentration was achieved through regular arterial blood gas analysis, and coagulation via analysis with thromboelastography. All patients had an indwelling urinary catheter inserted prior to the commencement of surgery.
Renal function was monitored with routine blood tests. For the purposes of this audit, pathology results for albumin, creatinine and urea were recorded preoperatively and at days one, three and five postoperatively. For the purposes of this audit, pathology results for haemoglobin concentration, platelets, International Normalized Ratio, prothrombin time, and activated partial thromboplastin time were recorded preoperatively and at days one, three and five postoperatively.
All patients had nasopharyngeal temperature probes inserted to enable core body temperature monitoring. During the surgical resection phase of the procedure, the risk of hypothermia was mitigated via the use of forced air warming blankets and warmed intravenous fluids. Strict temperature control was particularly important during the HIPEC phase, wherein the introduction of heated chemotherapy agent directly into the peritoneal cavity could cause changes in temperature and metabolic rate; as such, cooled intravenous fluids were used to prevent systemic hyperthermia. There were no set criteria to determine which fluid management strategy should be used and this decision was left to the discretion of the anaesthetist based on clinical assessment.
Blood products were transfused in the event of excessive intraoperative blood loss. As this was a retrospective audit, there was no standardisation of the triggers for the transfusion of blood and blood products. The use of packed red cells (PRBC), fresh frozen plasma, platelets and cryoprecipitate was at the discretion of the anaesthetist based on clinical and laboratory assessments. With regard to intraoperative transfusion, only broad guidelines exist at our institution which recommend maintaining haemoglobin between 80 and 100 g/l. As such, the transfusion trigger was a haemoglobin value of 80 g/l or below with ongoing blood loss. Patients were administered a vasoactive infusion, most commonly noradrenaline, titrated to maintain a predetermined mean arterial pressure. Some patients received intraoperative steroids and tranexamic acid; however, there was no protocol, so the decision regarding whether to administer tranexamic acid and steroids was made by the treating anaesthetist on a case-by-case basis. All patients were transferred to the intensive care unit (ICU) postoperatively and were given patient-controlled analgesia (PCA) and total parenteral nutrition as required. The Clavien-Dindo classification of surgical complications 19 , as summarised in Table 2 , was used to grade postoperative complications. All patients had postoperative Doppler ultrasound of their limbs to check for the presence of thrombi. Prophylactic low molecular weight heparin was administered to all patients as per the postoperative deep vein thrombosis (DVT) prevention protocol at our centre.
Statistical methods
Data was extracted from patient records and inserted into an Excel 2007 spreadsheet (Microsoft, Redmond, WA, USA). Data was transferred to SPSS Statistics v23 (IBM, Armonk, NY, USA) for statistical analysis. Descriptive statistics such as patient demographics and intraoperative changes were presented as medians and ranges for continuous variables, and as counts and percentages for categorical variables. For the purposes of comparison with other studies, mean values were used. Statistical analysis was done using a Mann-Whitney U test for comparisons between patients in the control group and those in the study group; multivariate linear regression or locally weighted scatterplot smoothing was used for comparing continuous measures. A Kaplan-Meier curve was used for survival analysis; chi-square test was used for comparisons in survival rates between patients who underwent CRS with HIPEC and those who underwent CRS with HIPEC and EPIC. It was not possible to estimate standard time to 50% survival due to the relatively short follow-up time, so a time to 75% survival was provided instead. A P value of <0.05 was considered to be statistically significant.
Patients were separated into two groups based on the following results: those who received intraoperative intravenous fluids less than 15 litres, and those who received more than 15 litres. Serum creatinine was used as the primary marker for renal function. Similarly, as we were interested in the effect of tranexamic acid, we compared intraoperative blood loss, intraoperative PRBC transfusion and postoperative complications between patients who received and who did not receive intraoperative tranexamic acid.
Results
A total of 70 patients were included in the audit of whom 33 were male (47.1%). The mean age was 51.46 years, the mean body mass index was 28.45 kg/m 2 , and the mean disease period was 15.63 months. The most common originating organ of disease was the appendix (74.3%). Patient demographic data is summarised in Table 3 . 
Fluid management and renal function
Patients received a median volume of 7,318 ml of crystalloid (range 3,000 to 28,000 ml) and 3,370 ml of colloid (range 200 to 13,750 ml) fluid. Median urine output was 2.76 ml/kg/hour (range 0.80 to 11.37 ml/kg/hour). Renal function was monitored with routine blood tests. The results for albumin, creatinine, and urea are summarised in Figure  1 . Postoperative acute renal failure, defined as an increase in serum creatinine of ≥1.5 times baseline, occurred in 7.15% (n=5) patients.
Fifty-three patients (76%) received <15 litres of intraoperative intravenous fluid and 17 patients (24%) received >15 litres. There was no statistically significant difference in postoperative creatinine (factoring for preoperative creatinine) between the two groups at either day one (P=0.80) or day three (P=0.76). Four patients in the <15 litre group (4/53, 7.5%) and one patient in the >15 litre group (1/17, 5.8%) developed postoperative acute renal failure.
Bleeding and the use of tranexamic acid
Reported median blood loss was 500 ml (range 0 to 10,000 ml). The administration of intraoperative blood products is summarised in Table 4 . The haemoglobin concentration, platelets, International Normalized Ratio, prothrombin time and activated partial thromboplastin time at days one, three and five postoperatively are summarised in Figure 2 .
Thirty patients (42.9%) received intraoperative tranexamic acid. The differences between the patients who received tranexamic acid and those who did not are summarised in Table 5 . Patients who received tranexamic acid had a lower median volume of intraoperative PRBC transfusion and a higher median haemoglobin concentration at day three postoperatively than those who did not; however, there Table 5 Comparison between patients who were administered intraoperative tranexamic acid and those who were not were no statistically significant differences between the two groups. When factoring for preoperative haemoglobin concentration, there was also no significant difference in median haemoglobin concentration between patients who received intraoperative tranexamic acid and those who did not at day one (P=0.27) and day three (P=0.25) postoperatively (Figure 3 ). Even when preoperative haemoglobin concentration was ignored, there was still no significant difference in median haemoglobin concentration between patients who received intraoperative tranexamic acid and those who did not at day one (P=0.54) and day three (P=0.07) postoperatively. Postoperative complications were compared between patients who were administered intraoperative tranexamic acid and those who did not, and are summarised in Figure 4 .
The incidence of DVT was markedly higher in patients who received intraoperative tranexamic acid (n=10) compared with patients who did not (n=1). Figures for other postoperative complications were similar between the two groups.
Intraoperative course
The majority of patients underwent CRS with HIPEC (n=42; 60.0%), with the remainder undergoing a combination of CRS, HIPEC and EPIC (n=25; 35.7%), and CRS alone (n=3; 4.3%). Information about operation type and duration, and the Sugarbaker completeness of cytoreduction score is summarised in Table 6 . All patients had multiple intraabdominal organs resected, with the most commonly resected organs being the greater omentum (n=59; 84%), lesser omentum (n=51; 73%), gallbladder (n=49; 70%), and the right hemicolon (n=49; 70%). Tissue samples from the resected organs were sent to an external histopathology laboratory for analysis. Most patients received an intraoperative vasopressor infusion (n=58; 82.9%). The most commonly used vasopressor was noradrenaline alone (n=41; 58.6%). Opioids were administered for intraoperative analgesia, including fentanyl (n=68; 97.1%; median 1,220 µg; range 200 to 3,312 µg) and morphine (n=24; 34.3%; median 49.5 mg; range 28 to 90 mg). Thoracic epidurals were utilised in four patients (5.7%). A total of 32 patients (45.7%) received intraoperative steroids.
All of the patients in the audit who underwent CRS with HIPEC received mitomycin C as the chemotherapeutic agent for a period of 90 minutes. Mitomycin C dose and infusion temperature are summarised in Table 6 . A total of 26 patients (37.1%) had EPIC for a median of four days (range 1 to 6 days).
Postoperative course
All 70 patients were transferred to ICU immediately after surgery and the median length of ICU stay was one day (range 0 to 8 days). Median extubation time from the end of surgery was 705 minutes (range 0 to 3420 minutes). Only three patients were transferred to ICU extubated (4.3%). The majority of patients were given vasopressor support in ICU (n=44; 62.9%) and total parenteral nutrition (n=69; 98.6%). Patents remained in hospital for a median of 22.5 days (range 4 to 335 days).
Early postoperative pain was treated using patientcontrolled analgesia (PCA) with fentanyl, morphine or oxycodone in all patients. The type of drug used for PCA was changed if the patient developed an adverse reaction, or if the drug did not help to adequately control pain despite increases in dose. Median PCA use was eight days (range 1 to 18 days). No significant difference in length of PCA use was found to exist between patients who had a thoracic epidural and those who did not (P=0.37).
Postoperative complications were graded using the Clavien-Dindo classification. This data is summarised in Figure 5 .
Survival analysis
Seventy patients were enrolled in this audit with three operation groups. As there were only three patients with CRS alone, these were dropped from the analysis for a total of 67 patients. Forty-two patients (62.7%) had CRS with HIPEC and 25 (37.3%) had CRS with HIPEC and EPIC.
There were no intraoperative deaths. A total of four patients (5.7%) died during their hospital admission due to sepsis or other complications related to their disease burden. Median follow-up time was 3.07 years. At one year's followup, six (9%) were deceased and at the end of the study 15 (22.4%) were deceased. All deaths recorded were considered to be associated with the illness. Between the first and last procedure there were 5.94 years and between the first procedure and the last follow-up date there were 6.94 years. On average, two patients are dying each year. Approximate time to 75% survival with CRS with HIPEC was 3.7 years whereas CRS with HIPEC and EPIC was 2.7 years. There was no significant difference in survival rates between the two procedures (P=0.38). Survival analysis of all patients is shown in Figure 6 .
Discussion
This was a single centre retrospective audit of the perioperative anaesthetic management of patients undergoing CRS with HIPEC for PMP, and evaluated whether the administration of intraoperative tranexamic acid led to improved outcomes.
A total of 30 patients (42.9%) were administered intraoperative tranexamic acid. Haemoglobin concentration at day one and day three postoperatively, corrected for preoperative haemoglobin concentration, was used as a surrogate marker of postoperative blood loss. Our results suggest that there was no significant difference in haemoglobin transfusion outcomes between patients who received intraoperative tranexamic acid and those who did not. However, there was a markedly higher incidence of DVT in patients who received tranexamic acid (n=10) compared to those who did not (n=1). The development of DVT could be explained by other factors, including preexisting comorbidities, and cannot be attributed to the use of tranexamic acid in this audit. Patients who received intraoperative tranexamic acid had a higher median haemoglobin concentration at day three than those who did not, but this was not statistically significant. Shakur et al 12 performed a randomised controlled trial with 274 sites and 20,211 patients, and found the administration of intraoperative tranexamic acid to be beneficial in patients undergoing CRS with HIPEC, with patients who were administered intraoperative tranexamic acid requiring significantly less intraoperative PRBC transfusion than those in the control group 12 . Although our study also found that patients who were administered intraoperative tranexamic acid required less intraoperative PRBC transfusion than those who were not, this difference was also not significant. This may be explained by the fact that the other study had a larger study population (n=201) than our study (n=70), as well as by differences in study design and patient management strategies. Patients in our study were administered intraoperative crystalloid and colloid intravenous fluid to maintain a urine output of greater than 0.5 ml/kg/hour. Our results showed that patients who received <15 litres had a similar incidence of postoperative renal failure (7.5%) to those who received >15 litres intravenous fluid (5.8%). Similarly, no significant difference in postoperative renal function existed between the two groups. Our rates of postoperative acute renal failure were higher than others previously reported 20 . This was despite the fact that patients in our study received a greater average volume of intraoperative fluid than in other studies 21, 22 , and that all patients had good intraoperative urine output. This suggests that other factors, such as the use of nephrotoxic drugs and pre-existing comorbidities, likely explain our findings. It also suggests that intraoperative urine output and total fluid infused are not the best predictors of postoperative renal function.
Average operating time in our study was 555.43 minutes. This is similar to the average operating time described in other studies 9, 10, 14, 21 . Intraoperative monitoring with the use of arterial lines, central venous lines, nasopharyngeal temperature probes, and indwelling urinary catheters was similar to practices described in other studies 14, 21 . Only 4.3% of patients were extubated in theatre, whereas other studies described 42% 14 and 100% 9 of patients being extubated in theatre. Patients in our study spent an average of 824 minutes ventilated in ICU, whilst other studies reported ICU ventilation times of 240 minutes 21 and 222 minutes 22 . These differences could be explained by differences in protocols or differences in clinical practice. The average number of days spent in ICU in our study was 1.84 days, which was similar to that reported in other studies 9, 10, 14, 21, 22 . The average hospital stay in our study was 36.61 days, which was longer than the 13.0 to 21.1 days reported in other studies 9,10,21 . Our centre is the only one in Queensland where CRS with HIPEC for PMP is performed, meaning that our patients come from all over the state. Patients are often discharged to places much greater distances from the hospital when compared with European centres, which can lead to prolonged hospital stays due to complex discharge planning.
Due to this being a retrospective audit, there are unavoidable limitations. We were reliant on data being accurately recorded in patient notes, with any deficiencies in the quality of the documentation adversely impacting our results. Furthermore, inherent limitations in the anaesthetic data recording software utilised in our hospital meant that the raw data was rarely available for analysis. For example, all intraoperative measurements of vital signs including blood pressure, pulse rate, temperature, and invasive pressures are converted to a graphical form at the end of the case, with the numerical data unable to be retrieved. Other sources of error include the lack of protocols at our centre regarding the management of patients undergoing CRS with HIPEC for PMP. Due to this, it was left to the discretion of the lead anaesthetist as to the particulars of the administration of amounts of intravenous fluid, blood and blood products, tranexamic acid, and triggers for transfusion. The median blood loss reported by anaesthetists is likely to have been particularly inaccurate. Moreover, all statistical comparisons were exploratory.
Conclusion
In conclusion, our audit findings confirm that the perioperative anaesthetic management of patients undergoing CRS with HIPEC for PMP is challenging due to the complexity of the procedure, prolonged surgical time, major blood loss and major intraoperative fluid shifts. Based on the outcomes of our audit, we cannot conclude that blood loss in patients undergoing CRS with HIPEC for PMP is influenced by the administration of tranexamic acid; however, tranexamic acid appeared to be associated with a higher incidence of DVT. We also cannot conclude that different intraoperative fluid strategies influence the incidence of acute kidney injury. Larger scale studies would be required to evaluate these and other interventions.
